NIH Hands Patent for Brain-Protecting Drug Tech to Startup
Published Date: 5/16/2025
Notice
Summary
The National Center for Advancing Translational Sciences plans to give Neurala Bio, Inc. an exclusive license to use new inventions related to c-Abl tyrosine kinase inhibitors, which could help develop important medicines. This means Neurala gets special rights to make and use these inventions, possibly speeding up drug research and development. The deal affects researchers, companies, and patients waiting for better treatments, with no immediate cost changes announced.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Exclusive Drug Patent License to Neurala
The National Center for Advancing Translational Sciences plans to give Neurala Bio, Inc. an exclusive patent license to inventions for c-Abl tyrosine kinase inhibitor compounds and their use. This could help speed up drug research and development and affect researchers, companies, and patients, and the notice states there are no immediate cost changes announced.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in